A new HIV-prevention drug is showing promising signs, but it's difficult to find in Africa and beyond
Summary
Lenacapavir, a long-acting HIV-prevention drug given twice a year, has shown strong protection in studies, but supply remains limited in Uganda and elsewhere. The U.S. Food and Drug Administration has tentatively approved a generic version for 120 low-income countries, which could lower the price and expand access, though advocates say current plans will not reach enough people quickly enough.Key Facts
- Lenacapavir is an HIV-prevention drug developed by Gilead Sciences and is administered twice a year.
- Studies have shown that lenacapavir can provide nearly complete protection from HIV.
- People in Mbarara, Uganda, report difficulty obtaining lenacapavir because clinics do not have enough doses.
- The FDA has tentatively approved a generic version of lenacapavir for use in 120 low-income countries.
- The generic version could cost about $40 per year, compared with a U.S. list price of $28,218.
- The Global Fund hopes to provide lenacapavir to 3 million people by the end of 2028.
- Doctors Without Borders says the planned supply and country coverage are insufficient and has urged Gilead to expand access.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
